Anti-Anxiety Drugs Like Valium and Xanax May Increase The Risk Of Miscarriage
AdviceHealth and Fitness 17 May 2019 Arabia Day Newsdesk 0
By Steven Reinberg
Latest Pregnancy News
WEDNESDAY, May 15, 2019 (HealthDay News) — Pregnancy is often a time of heightened worry. But researchers warn that taking anti-anxiety drugs like Valium and Xanax may increase the risk of miscarriage.
Called benzodiazepines, these powerful drugs have long been prescribed to treat a variety of mood disorders. However, a new Canadian study finds that when taken in early pregnancy, they raise the risk for a miscarriage in the first trimester by 11%.
Medication use in pregnancy is a tricky business, experts say.
“In medications in pregnancy, physicians have to decide, are the risks higher than the benefits, because there isn’t any risk zero,” said lead researcher Anick Berard. She’s a professor at the Centre Hospitalier Universitaire Sainte-Justine in Montreal.
In this case, doctors must balance the severity of the woman’s mood problem against possible harm to the developing fetus, she said.
For the study, Berard and her colleagues collected data on about 442,000 pregnant Canadians from 1998 through 2015.
The study found that 6% of pregnancies ended in a miscarriage. Among those who miscarried, slightly more than 1% were taking a benzodiazepine for the first time in early pregnancy.
Berard said that it didn’t matter which benzodiazepine a woman took, as all were linked with an increased risk for miscarriage. Besides Valium (diazepam) and Xanax (alprazolam), this class of drugs includes Ativan (lorazepam) and Klonopin (clonazepam).
Berard cautioned, however, that this study can’t prove that tranquilizers cause miscarriages, only that an association exists.
And the researchers were unable to account for smoking and alcohol use, which may also increase risk for miscarriage.
Exactly how these drugs are linked with a failed pregnancy isn’t known. But animal studies have shown that benzodiazepines affect fetal development and raise miscarriage odds, Berard said.
And she stressed that although benzodiazepines may negatively affect pregnancy, so can anxiety and insomnia.
Women should not stop taking their benzodiazepines, but should have a discussion with their doctor about the risks and benefits of these drugs, Berard said.
“Anxiety and insomnia are serious mental health issues, and they are relatively common in pregnancy,” said Catherine Monk, a professor of medical psychology in obstetrics and gynecology at Columbia University.
“Anxiety can affect up to 15% of pregnant women, almost two times the rate of gestational diabetes,” said Monk, who wasn’t involved in the study.
But far too often, she said, primary care doctors or obstetricians prescribe benzodiazepines rather than refer expectant mothers to a mental health professional for evaluation and non-drug treatment.
Psychotherapists have a variety of tools, Monk said. They can encourage good sleep habits, help set up a “worry book,” and advise meditation. Using what’s called cognitive behavioral therapy, they also can teach patients to see worries from different perspectives and to use relaxation techniques, she said.
“Typically, some of these different techniques provide immense relief from anxiety and insomnia,” Monk noted.
Dr. Rahul Gupta, chief medical and health officer at the March of Dimes, said benzodiazepines also increase the risk of preterm birth and low birth weight infants.
“This study reinforces the fact that these drugs have a risk potential that is significant and needs to be discussed with the patient,” he said.
Patients should be offered “non-pharmacological therapies as well as other pharmacological options if the non-pharmacological options do not work,” he added.
The report was published online May 15 in the journal JAMA Psychiatry.
Copyright © 2019 HealthDay. All rights reserved.
SOURCES: Anick Berard, Ph.D., professor, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada; Catherine Monk, Ph.D., professor, medical psychology in obstetrics and gynecology, Columbia University, New York City; Rahul Gupta, M.D., M.P.H., senior vice president and chief medical and health officer, March of Dimes; May 15, 2019, JAMA Psychiatry, online
No comments so far.
Be first to leave comment below.